Impact of baseline patient and disease characteristics on overall survival: univariate and multivariate Cox regression analysis
| Total N (%) | Univariate analysis | P value | Multivariate analysis | P value | |
| HR (death) (95% CI) | HR (death) (95% CI | ||||
| Gender | |||||
| Male | 240 (63.2) | 1 | 1 | 0.855 | |
| Female | 140 (36.8) | 0.94 (0.69 to 1.27) | 0.682 | 1.35 (0.70 to 1.50) | |
| Age (years) at the time of CombiIT | |||||
| <54 | 153 (40.3) | 1 | 0.616 | 1 | 0.689 |
| 54–64 | 105 (27.6) | 1.13 (0.78 to 1.62) | 1.17 (0.75 to 1.81) | 0.491 | |
| >64 | 122 (32.1) | 1.19 (0.83 to 1.70) | 1.20 (0.76 to 1.90) | 0.428 | |
| BRAF status | |||||
| BRAF wild type | 138 (36.3) | 1 | 0.962 | 1 | |
| BRAF mutant | 242 (63.7) | 0.99 (0.72 to 1.37) | 1.13 (0.76 to 1.67) | 0.548 | |
| LDH level* | |||||
| Normal | 189 (51.4) | 1 | < 0.0001 | 1 | 0.069 |
| Elevated | 133 (36.1) | 1.24 (0.88 to 1.74) | 1.05 (0.69 to 1.59) | 0.831 | |
| 2×>ULN | 46 (12.5) | 2.53 (1.67 to 3.83) | 1.80 (1.05 to 3.09) | 0.031 | |
| S100B level* | |||||
| Normal | 109 (32.8) | 1 | 0.099 | 1 | 0.325 |
| Elevated | 156 (47) | 1.35 (0.92 to 2.00) | 1.39 (0.90 to 2.11) | 0.135 | |
| 10×>ULN | 67 (20.2) | 1.61 (1.02 to 2.54) | 1.30 (0.76 to 2.24) | 0.341 | |
| Number of MBM at the time of CombiIT* | |||||
| 1–3 | 167 (46.8) | 1 | 0.001 | 1 | 0.008 |
| >3 | 190 (53.2) | 1.74 (1.26 to 2.40) | 1.67 (1.14 to 2.44) | ||
| ECOG-PS* | |||||
| 0 | 249 (66.4) | 1 | 0.001 | 1 | 0.006 |
| 1 | 87 (23.2) | 1.3 (0.91 to 1.87) | 1.31 (0.87 to 1.99) | 0.188 | |
| >1 | 39 (10.4) | 2.58 (1.66 to 4.00) | 2.42 (1.39 to 4.20) | 0.002 | |
| Presence of symptomatic MBM* | |||||
| No | 133 (69) | 1 | |||
| Yes | 60 (31) | 1.46 (0.96 to 2.23) | 0.078 | N/A |
Bold values indicate statistically significant results (p<0.05).
*Denotes variables for which the missing/unknown values were excluded from the analysis.
CombiIT, nivolumab plus ipilimumab; ECOG-PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain metastases; N, number of patients in each subgroup; N/A, not performed for this factor, since information was available to only 50% of the patients; ULN, upper level normal.